Avalo Therapeutics(NASDAQ) AVTX

Avalo Therapeutics makes medicines for painful immune diseases. These treatments target proteins that cause inflammation and harm. They help patients who have few other medical options.

What is in the Pipeline?

• Abdakibart (AVTX-009): Monoclonal antibody designed to block IL-1 beta, a protein that triggers inflammation; currently in Phase 2 clinical trials for a chronic skin condition called hidradenitis suppurativa.
• Strategic Assets: Portfolio including quisovalimab and various small molecule inhibitors; company is exploring strategic alternatives or partnerships for these development programs.
• Rare Disease Candidates: Substrate replacement therapies for genetic disorders like PGM1 deficiency; these products were previously in Phase 3 clinical trials but are no longer the primary development focus.

Strategic Deals and Major Acquisitions

• Acquired AlmataBio, Inc. in the first quarter of 2024 to gain access to the abdakibart development program.
• Entered a world-wide exclusive license agreement with Eli Lilly and Company to develop and commercialize targeted immune therapies.
• Secured drug compound rights through an agreement with Leap Therapeutics, Inc. following the purchase of AlmataBio, Inc.
• Finished patient enrollment in the Phase 2 LOTUS trial for hidradenitis suppurativa in October 2025.

Precision Focus on Chronic Inflammation

The company uses precision medicine to target IL-1 beta, a protein that drives many autoimmune and inflammatory disorders. By focusing on biologics, which are medicines derived from living systems, Avalo aims to treat debilitating skin diseases that do not respond to existing therapies.

Analyzing the Financial Progress

• Revenue reached $59,000 in Q4 2025, down 69.3% from the $192,000 reported in Q4 2024.
• Net loss narrowed to -$13.7 million in Q4 2025, showing a 61.2% improvement from the -$35.3 million loss in Q4 2024.
• Operating cash flow was -$14.2 million in Q4 2025, improving 5.3% compared to the prior year.
• Market capitalization rose to $243.4 million in Q4 2025, representing a 212.9% increase over Q4 2024.

A Significant Corporate Transformation

Avalo has evolved from a broad rare disease specialist into a streamlined developer of targeted immune therapies. Its current strategy centers on advancing a single lead biologic candidate toward potential regulatory approval.